Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access.

By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024.

Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC).

By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024.

By product, the market is segmented into Lutetium‑177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
• By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others.

Research Coverage

This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market.

Reasons to buy this report

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.

Show more